AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)

Grant

Total Award Amount

  • 9000.00
  • Direct Costs

  • 6923.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator